Results 201 to 210 of about 5,561 (244)

Immunoreactive Insulin, Glucose Tolerance, and Carbohydrate Inducibility in Types II, III, IV, and V Hyperlipoproteinemia

, 1969
Charles J. Glueck, Robert I. Levy, Donald S. Fredrickson   +2 more
openalex   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Diagnosis and Management of Type I and Type V Hyperlipoproteinemia

Journal of Atherosclerosis and Thrombosis, 2012
Hidenori Arai, Toshio Hayashi, Yasuhiro Matsubayashi   +2 more
exaly  

Therapeutic Apheresis for Management of Lp(a) Hyperlipoproteinemia

Current Atherosclerosis Reports, 2020
S N Pokrovsky, Olga I Afanasieva
exaly  

APOA5 genetic variants are markers for classic hyperlipoproteinemia phenotypes and hypertriglyceridemia

Nature Clinical Practice Cardiovascular Medicine, 2008
Sonia S Anand, Salim Yusuf, Robert A Hegele   +2 more
exaly  

Type 1 hyperlipoproteinemia due to a novel deletion of exons 3 and 4 in the GPIHBP1 gene

Atherosclerosis, 2014
Kjetil Retterstøl, Stefano Romeo, Jiajun Gu   +2 more
exaly  

Diet and probucol in lowering cholesterol concentrations. Additive effects on plasma cholesterol concentrations in patients with familial type ii hyperlipoproteinemia

, 1977
J. LeLorier
openalex   +1 more source

Lipoprotein Apheresis in Patients With Maximally Tolerated Lipid-Lowering Therapy, Lipoprotein(a)-Hyperlipoproteinemia, and Progressive Cardiovascular Disease

Circulation, 2013
Reinhard Klingel
exaly  

Safety and Tolerability of Long Lasting LDL-apheresis in Familial Hyperlipoproteinemia

Therapeutic Apheresis and Dialysis, 2007
Milan Bláha, Vladimír Blaha, Stanislav Filip   +2 more
exaly  

Loss-of-Function Homozygous Variant in LPL Causes Type I Hyperlipoproteinemia and Renal Lipidosis

Kidney International Reports, 2023
exaly  

Efficacy of pitavastatin for the treatment of non‐alcoholic steatohepatitis with dyslipidemia: An open‐label, pilot study

Hepatology Research, 2011
Etsuko Hashimoto
exaly